Skip to content

Sector benchmark

Where does a company stand against its sector? Every ratio over five fiscal years, with its place among its peers and what that means, ready to print for your client.

Sector benchmark

BRUPHARM PHARMALAB

BE 0785.641.404
NACE 46.460, Wholesale of pharmaceutical and medical goods
NACE division 46, Wholesale trade all sizesfiscal years 2022 to 20243,384 to 30,289 sector peers per ratio

Summary

fiscal year 2024

BRUPHARM PHARMALAB does better than half of its sector on 2 of the 13 ratios compared.

most favourable quarter above the median below the median least favourable quarter
Strongest points
  • Debt to equitybetter than 93%
  • Days inventorybetter than 56%
Points to watch
  • Current ratiobetter than 5%
  • Quick ratiobetter than 5%
  • Working-capital ratiobetter than 5%

Solvency and debt

How soundly the company is financed.
Solvency
-46.3%▼2024

Solvency is below 93% of 30,205 sector peers: in the least favourable quarter.

Position against the sector weakening since 2022.

202220232024
Debt to equity
-3.16▼2024

Debt to equity is below 93% of 29,964 sector peers: in the most favourable quarter.

Position against the sector improving since 2022.

202220232024
Interest coverage
-12.67▲2024

Interest coverage is below 91% of 26,293 sector peers: in the least favourable quarter.

Position against the sector stable since 2022.

202220232024

Liquidity

Whether it can pay its short-term bills.
Current ratio
0.12▼2024

The current ratio is below 95% of 29,924 sector peers: in the least favourable quarter.

Position against the sector stable since 2022.

202220232024
Quick ratio
0.10▼2024

The quick ratio is below 95% of 29,956 sector peers: in the least favourable quarter.

Position against the sector stable since 2022.

202220232024
Working-capital ratio
-129.2%▼2024

The working-capital ratio is below 95% of 30,139 sector peers: in the least favourable quarter.

Position against the sector stable since 2022.

202220232024

Profitability

What the company earns on its assets and its sales.
Return on equity
-122.7%2022

Return on equity is below 95% of 25,070 sector peers: in the least favourable quarter.

202220232024
Return on assets
-18.5%▼2024

Return on assets is below 91% of 30,289 sector peers: in the least favourable quarter.

Position against the sector stable since 2022.

202220232024
Net margin
-90.3%▲2024

The net margin is below 95% of 4,050 sector peers: in the least favourable quarter.

Position against the sector stable since 2022.

202220232024
EBITDA margin
-13.4%▲2024

The EBITDA margin is below 95% of 3,641 sector peers: in the least favourable quarter.

Position against the sector stable since 2022.

202220232024
Gross margin
0.7%▲2024

The gross margin is below 91% of 3,909 sector peers: in the least favourable quarter.

Position against the sector stable since 2022.

202220232024

Working-capital cycle

How long cash is tied up in customers, suppliers and stock.
Days sales outstanding
258days▼2024

Days sales outstanding is above 94% of 4,008 sector peers: in the least favourable quarter.

Position against the sector stable since 2022.

202220232024
Days payable outstanding
184days▲2024

Days payable outstanding is above 90% of 4,030 sector peers.

202220232024
Days inventory
47days▼2024

Days inventory is below 56% of 3,384 sector peers: more favourable than the median.

Position against the sector stable since 2022.

202220232024

Not computable

Long-term debt ratio. This company files the abbreviated or micro schema, in which turnover and purchases are optional; margins and credit terms therefore cannot be taken from its figures.

Source: filed annual accounts (NBB) and main activity (CBE register). Compared per fiscal year with each peer's latest statutory accounts; at least 30 peers per ratio. Prepared on 27 September 2026 via checked.be.